Oncotelic Therapeutics (OTC:OTLC) Stock, Quote.Headers.trade-ideas

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Screenshot 2024-05-31 at 8.39.16 PM

Biotech

General

OTLC

This Biotech Company&#39;s Lead Candidate Treats Rare Cancers As Well As Covid-19

Screenshot 2024-05-28 at 5.34.55 PM

News

CPMV

IOVA

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

Screenshot 2024-04-08 at 5.30.32 PM

With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial

ONCOTELIC THERAPEUTCS INC by Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc

Needham analyst Quinn Bolton maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Buy and raises the price target from $140 to $150.

Price Target

Analyst Ratings

SLAB

Needham Maintains Buy on Silicon Laboratories, Raises Price Target to $150

Benchmark analyst Cody Acree upgrades Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) from Hold to Buy and maintains the price target from $160 to $160.

Upgrades

Benchmark Upgrades Silicon Laboratories to Buy, Maintains Price Target to $160

Japanese automaker Toyota Motor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) on Wednesday hiked its full-year operating income outlook by 400 billion yen ($2.62 billion) to 4,700 billion yen for the financial year ending March 2025.
Upbeat Forecast: The company now expects full-year sales revenue of 47,000 billion yen and a margin of 10%, up from its previous forecast of 9.3%. 
The revised forecast reflects the company&#8217;s progress in strengthening earnings power and efforts to improve product competitiveness and value chain earnings, it said.
Weak Quarterly Results: The upbeat forecasts, however, follow a weak quarterly report. Toyota reported an operating income of 1.22 trillion yen for the three months through December, marking a drop of about 28% from the corresponding period last year, owing to a significant drop in operating income in Japan and North America.
Sales revenue in the period, however, rose marginally to 12.39 trillion yen.
Why It Matters: Toyota retained its position as the world's best-selling automaker in 2024 after <a href="https://www.benzinga.com/tech/25/01/43380849/toyota-retains-top-selling-automaker-position-while-continuing-to-trail-tesla-byd-in-ev-sales">reporting 10.8 million sales</a>, marking a dip of 4% from a year ago.
The sales numbers include those of the company's Lexus brand as well as its subsidiaries Daihatsu and Hino. Daihatsu reported sales of 536,588 units worldwide in 2024 while Hino reported sales of 125,556 units.
German automaker Volkswagen Group, in comparison, sold only about 9 million vehicles last year.
Price Action: Toyota&#8217;s NYSE-listed shares are up 2.9% in pre-market trading. The stock stock closed at $187.56 on Tuesday, down 7.6% over the past year, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro.</a> 
(1 Japanese Yen = $0.0065)
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43486319/tesla-bear-expects-ev-giants-earnings-to-fall-below-bullish-estimates-in-2025-notes-majority-of-companys-revenues-come-from-car-deliveries" target="_blank" rel="noreferrer noopener">Tesla Bear Expects EV Giant's Earnings To Fall Below Bullish Estimates In 2025, Notes Majority Of Company's Revenues Come From Car Deliveries</a></li>
</ul>
Photo courtesy: Shutterstock

Markets

Tech

Toyota Stock Rises 3% Pre-Market After It Upgrades Full Year Forecast Despite Drop In Q3 Earnings

Telsey Advisory Group analyst Dana Telsey maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Market Perform and maintains $76 price target.

Telsey Advisory Group Maintains Market Perform on Estee Lauder Cos, Maintains $76 Price Target

DA Davidson analyst Linda Bolton Weiser maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $171 to $169.

DA Davidson Maintains Neutral on Clorox, Lowers Price Target to $169

Mizuho analyst Ben Chaiken downgrades Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) from Outperform to Neutral and raises the price target from $243 to $263.

Downgrades

Mizuho Downgrades Hilton Worldwide Holdings to Neutral, Raises Price Target to $263

Needham analyst Mike Matson reiterates TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Hold to Hold.

Reiteration

TMDX

Needham Reiterates Hold on TransMedics Grto Hold

DA Davidson analyst Linda Bolton Weiser maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Buy and maintains $170 price target.

DA Davidson Maintains Buy on e.l.f. Beauty, Maintains $170 Price Target

Needham analyst Kyle Peterson reiterates Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and maintains $2500 price target.

FICO

Needham Reiterates Buy on Fair Isaac, Maintains $2500 Price Target

Snacks giant Mondelez International&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) shares are trading lower in <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket on Wednesday</a>.
The company reported fourth-quarter sales growth of 3.1% year-on-year to $9.60 billion, missing the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43478380/mondel-z-international-reports-q4-and-fy-2024-results" rel="noreferrer noopener">consensus estimate of $9.64 billion</a>.
Adjusted EPS of $0.65 also <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the consensus estimate of $0.66.</a>
Revenues in Asia, Middle East&nbsp;&amp; Africa surged 9.9% whereas Latin America plunged 7.2%. Revenue from Europe and North America increased 5.8% and 0.1% respectively.
Gross profit for the quarter climbed 6.9% to $3.71 billion and the gross margin expanded 130 basis points to 38.6%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43462736/cosmetics-major-estee-lauder-q2-earnings-sales-slump-restructuring-deepens-but-ceo-bets-on-beauty-reimagined" rel="noreferrer noopener">Cosmetics Major Estee Lauder Q2 Earnings: Sales Slump, Restructuring Deepens, But CEO Bets On &#8216;Beauty Reimagined&#8217;</a>
Operating income jumped 35% to $1.61 billion and the operating margin expanded 400 basis points to 16.8%.
The operating cash flow for the twelve months totaled $4.9 billion, with a free cash flow of $3.5 billion.
&#8220;As we transition into 2025, we remain focused on executing against our long-term growth strategy and delivering on our chocolate business playbook to navigate unprecedented cocoa cost inflation,&#8221; said Chair and CEO Dirk Van de Put.
Outlook: Mondelez expects FY25 organic net revenue growth <a href="https://www.benzinga.com/calendars/guidance">to be approximately 5%.</a>
The company expects adjusted EPS to decline approximately 10% on a constant currency basis due to unprecedented cocoa cost inflation.
Mondelez sees FY25 free cash flow of over $3 billion.&nbsp;The company estimates currency translation would decrease full-year net revenue growth by approximately&nbsp;2.5%&nbsp;and negatively impact Adjusted EPS by $0.12.
Price Action: MDLZ shares are trading lower by 4.44% at $53.63 in premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43463646/alcohol-giant-diageo-suspends-guidance-as-trumps-tariff-looms" target="_blank" rel="noreferrer noopener">Alcohol Giant Diageo Suspends Medium-Term Guidance As Trump&#8217;s Tariff Looms</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Guidance

Movers

Trading Ideas

MDLZ

Snacks Giant Mondelez Q4 Earnings: Sales Miss, EPS Falls Short, Cocoa Inflation Threatens 2025 & More

Needham analyst Matt Dezort reiterates Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Buy and maintains $67 price target.

VRNS

Needham Reiterates Buy on Varonis Systems, Maintains $67 Price Target

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index For January 50.8 Vs. 51.2 Est.; 51.1 Prior

Baird analyst Peter Arment upgrades Mercury Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) from Neutral to Outperform and raises the price target from $37 to $58.

MRCY

Baird Upgrades Mercury Sys to Outperform, Raises Price Target to $58

U.K. Composite Purchasing Managers' Index For January 50.6 Vs. 50.9 Est.; 50.4 Prior

Toyota Motor Reported Q3 Toyota and Lexus Vehicle Sales Of 2.73M

Toyota Motor Expects FY25 Revenue Of $309.21B Vs $291.4B Est And EPS Of $29.74 Vs $19.84 Est

PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) reported a <a href="https://www.benzinga.com/25/02/43460249/pepsicos-q4-sales-miss-estimates-on-downcast-performance-in-north-america-stock-dives">mixed fourth quarter</a>, missing revenue while beating earnings per share estimates. The management highlighted key strategic changes to its snack business Frito-Lay North America, which manufactures popular products like Lays, Cheetos, and Doritos.
What Happened: Frito-Lay North America (FLNA) experienced a decline in organic revenue for both the full year 2024 and the fourth quarter. Full-year organic revenue decreased by 0.5%, a significant drop from the 9% growth seen in 2023. In the fourth quarter alone, organic revenue was down 2%.
PepsiCo reinvested heavily in FLNA in Q4, funded partly by one-time gains, to revitalize volume growth. This included tactical spending and strategic groundwork for 2025.
The chairman and CEO of the company, Ramon Luis Laguarta in response to an analyst during its earnings call said, &#8220;We reinvested most of the one-time gains in building the infrastructure to capture those opportunities in 25.&#8221;
The management also highlighted that FLNA is emphasizing value offerings at different price points and pack sizes. This is alongside healthier options like products with lower sodium, and fat, better ingredients, and plant-based items. The management is addressing consumer preferences for &#8220;positive choices&#8221; and &#8220;permissible offerings.&#8221;
PepsiCo Beverages North America organic revenue increased 1% in 2024, which compares to 7% organic revenue growth in the prior year, whereas, Quaker Foods North America organic revenue declined 14 percent in 2024.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43487630/trump-media-or-trump-coin-where-have-investors-lost-more-money-since-the-47th-president-entered-the-white-house">Trump Media or Trump Coin: Where Have Investors Lost More Money Since the 47th President Entered the White House?</a>
Why It Matters: Laguarta said, &#8220;I think there&#8217;s a higher level of awareness in general of American consumers toward health and wellness, driven by conversations around obesity drugs, and other health-related topics. This increased awareness is influencing consumer behavior, which PepsiCo is addressing through its strategies&#8221;.
Fourth-quarter sales fell slightly short of expectations, decreasing 0.2% year-over-year to $27.78 billion compared to the projected $27.89 billion. However, adjusted EPS of $1.96 beat the $1.94 consensus.
For the next full year, PepsiCo projects low single-digit organic sales growth for 2025, anticipating a gradual improvement in North America. They reaffirmed their long-term targets of 4-6% organic sales growth and high single-digit EPS growth.
Restructuring efforts aim to boost international growth and North American efficiency, the management highlighted. PepsiCo also said that it is mindful of macroeconomic uncertainties and evolving consumer behavior, including the potential impact of weight loss drugs, though no direct impact has been observed.
Price Action: Shares of PepsiCo fell 4.51% to end Tuesday at $143.49 apiece. It rose by 0.49% in after-hours. The exchange-traded fund tracking the S&amp;P 500 index, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.67% to $601.78 on Tuesday.
The average price target among 20 analysts <a href="https://www.benzinga.com/quote/PEP/analyst-ratings">tracked by Benzinga</a> is $178.35 with a ‘hold' rating. The estimates range from $155 to $200 apiece. Recent ratings from RBC Capital, JP Morgan, and Deutsche Bank suggest a $171.67 target, implying a potential upside of 19.05%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/PEP/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="383" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05034243/PepsiCo-ANR-1024x383.png" alt="" class="wp-image-766528" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05034243/PepsiCo-ANR-1024x383.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05034243/PepsiCo-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05034243/PepsiCo-ANR-768x287.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05034243/PepsiCo-ANR.png 1068w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43459342/chip-equipment-maker-applied-materials-stock-is-up-over-9-ytd-even-as-charts-point-to-bearish-patterns-heres-what-investors-should-look-at">Chip Equipment Maker Applied Materials Stock Is Up Over 9% YTD Even As Charts Point To Bearish Patterns: Here&#8217;s What Investors Should Look At</a></li>
</ul>
Photo courtesy: Shutterstock

PepsiCo Revamps Lays, Cheetos, And Doritos Maker Frito Lay As North American Sales Take A Hit, Shifts Focus To Health-Conscious Customers

Earnings Beats

Toyota Motor Q3 2025 GAAP EPS $14.34 Up From $6.81 YoY, Sales $80.988B Beat $73.981B Estimate

CANG

Cango Announced Number Of Bitcoins Produced Stood At 538.2 In January 2025

Morgan Stanley&#8217;s CIO&nbsp;cautioned investors regarding the risks of President, Donald Trump&#8216;s growth-negative policies such as <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43454424/china-strikes-back-new-tariffs-up-to-15-on-certain-us-imports-in-retaliation-for-trumps-10-levy-on-chinese-goods">tariffs </a>and immigration enforcement. 
What Happened: The Chief U.S. Equity Strategist and CIO of&nbsp;Morgan Stanley, Mike Wilson, predicted weak stock returns for the S&amp;P 500 in&nbsp;the next 3 to 6&nbsp;months.
He pointed out that the &#8220;equity negative&#8221; policies were introduced before the &#8220;equity positive&#8221; measures had sufficient time to take effect in the form of less crowding out and lower interest rates. He mentioned deregulation, tax extensions, and reduced government spending as some of these &#8216;equity-positive&#8217; measures.
He cautioned about tough times ahead and predicted the S&amp;P 500 to trade between $5,500-$6,100 in&nbsp;the next 3 to 6&nbsp;months, with a fourth-quarter price target of $6,500. &#8220;Since we have been expecting tariffs to be implemented, this realization only furthers our preference for consumer services over goods. It also supports our preference for financials and other domestically geared businesses that have limited currency or trade exposures,&#8221; added the Morgan Stanley CIO.
The Morgan Stanley top strategist believes that DeepSeek&#8217;s latest AI model has added another level of uncertainty for investors and reiterated his preference for software and media over semiconductors. However, BofA&#8217;s Vivek Arya stated <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43474406/nvidia-still-a-top-pick-as-microsoft-meta-stick-with-gpus-despite-deepseek-challenge-analyst">yesterday </a>&#8220;Despite DeepSeek&#8217;s supposed ‘revolutionary' optimizations, there is no change thus far to spending intentions at Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) large customers including Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).&#8221;
SEE ALSO: <a href="https://www.benzinga.com/25/02/43426111/openai-rethinks-open-source-as-deepseek-gains-ground-sam-altman-hints-at-major-changes-in-ai-model-development">DeepSeek Impact Makes OpenAI Rethink Open Source — Sam Altman Hints At Major Changes In Model Development</a>
Why It Matters: In the last two weeks since President Trump&#8217;s inauguration, the market has been nearly flat, with the S&amp;P 500 slipping 0.18% since Jan. 20. Trump&#8217;s announcement of a 25% <a href="https://www.benzinga.com/markets/cannabis/25/02/43476012/trumps-canada-tariffs-bffs-for-decades-what-went-wrong-can-it-really-be-about-fentanyl-unlikely">tariff on imports from Canada and Mexico</a>, which has been postponed by a month. 
Prior to that, the announcement of <a href="https://www.benzinga.com/startups/25/02/43476917/deepseek-a-trojan-horse-kevin-oleary-calls-bs-on-deepseeks-6m-budget-claims-they-ripped-off-60k-nvidia-chips-from-the-black-market">DeepSeek unsettled the technology sector</a>, triggering a brief market selloff.
In addition to Morgan Stanley, economists at Goldman Sachs have raised concerns about the imposition of tariffs. They estimate that for every 5-percentage-point increase in the tariff rate, the S&amp;P 500&#8217;s earnings per share could decline by approximately 1% to 2%.
<ul>
<li>READ MORE: <a href="https://in.benzinga.com/25/02/43439462/us-manufacturing-confidence-tops-forecasts">US Manufacturing Confidence Tops Forecasts, Yet Price Pressures Intensify, &#8216;Could Become A Concern,&#8217; Economist Says</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

MSFT

NVDA

Expect Weak Stock Returns For Next 3 Months, Cautions Top Analyst Amid Trump's Trade And Immigration Policies

Press Releases

ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024

ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING

ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING

ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

Oncotelic Therapeutics Implements PDAOAI Platform

Oncotelic Therapeutics

Screenshot 2024-02-20 at 6.43.25 PM

Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments

Comments

Oncotelic Therapeutics

Oncotelic Therapeutics (OTLC) Forecast

Oncotelic Therapeutics (OTC:OTLC) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga